bortezominb and dexamethasone
PreclinicalSmall molecule
bortezominb and dexamethasone is one of 44 small molecule programs targeting Amyloidosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
76 competitors in Amyloidosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbPhase 3
Ninlaro
TakedaPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
Darzalex
Johnson & JohnsonPhase 2
Onpattro
Alnylam PharmaceuticalsPhase 2
Venclexta
AbbViePhase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Alkeran
AApotex Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- ZZhi-Hong Liu, M.D.